Edelman represents Amgen as it moves to acquire Horizon Therapeutics for $27.8B, making it the biggest healthcare deal for the year.

Horizon produces medicines for rare autoimmune and severe inflammatory diseases. Tepezza, its top drug, treats thyroid eye disease, and helped boost Horizon’s revenues up 47 percent to $3.2B during the past year.

Robert Bradway, Amgen’s CEO, said the deal fits his company’s “strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases.”

He also noted that drugs in Horizon’s pipeline complement Amgen’s R&D portfolio.

Horizon disclosed last month that it was considering takeover offers from Johnson & Johnson and Sanofi.

Dublin-based Amgen trades on the NASDAQ.

Lex Suvanto, CEO of Edelman financial communications; Jamaal Mobley, executive VP; and Shannon Susko, Edelman Smithfield healthcare head, are working on the deal.

They are joined by Edelman Ireland CEO Joe Carmody, corporate head Piaras Kelly and Edelman Global Advisory managing director Feargal Purcell.